ADC Therapeutics Reports Q3 2026 Earnings: GAAP EPS at $-0.16, Revenue at $21. ...

GuruFocus | Nov 9, 2026 10:01 AM EST

ZYNLONTA Sales Growth and Cost Discipline Cut Net Loss, While Restructuring Reshapes the Balance Sheet Related Stocks: ADCT ,